Bahija Jallal, PhD

Executive Vice President of AstraZeneca, Head of MedImmune

Dr. Bahija Jallal is Executive Vice President of AstraZeneca and Head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK. She has guided the MedImmune R&D organization through unprecedented expansion of its biologics pipeline from 40 drugs to more than 120 today. She inspires creativity, out-of-the-box thinking and a dedication to scientific excellence to the more than 2,500 employees at MedImmune.

She received a master’s degree in biology from the University of Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, and the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory member of the Healthcare Business Women’s Association. She is one of FierceBiotech’s 2011 Women in Biotech. She has received Washington Business Journal’s Women Who Mean Business Award, the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research, and the Maryland International Business Leadership Awards.